The First 100 Days: FDA's Frank Torti Outlines His Vision for the Agency
This article was originally published in RPM Report
Executive Summary
The FDA Science Board report highlighted a number of areas in which the agency's scientific and regulatory processes need improvement. Frank Torti, FDA's recently named chief scientist and second-in-command at the agency proposes an agenda on how the agency will respond.